Clinical Trial Update: Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST [Phase 2]

View source ↗

Summary

Phase 2 study of preoperative and postoperative imatinib mesylate for c-KIT positive gastrointestinal stromal tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (imatinib mesylate) (imatinib mesylate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED